A self-deletion lentiviral vector to reduce the risk of replication-competent virus formation

Journal of Gene Medicine

Volumn 15, Issue 2, 2013, Pages 102-112

  Fang, Yudan ^a,c   Gong, Xiuli ^a,c   Xu, Miao ^a,c   Zeng, Fanyi ^a,b,c   Zhang, Jingzhi ^a,c  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c BEIJING HOSPITAL   (China)

Author keywords

Cre loxP; In vivo applications; Lentiviral vector; Replication competent lentiviruses; Self deletion

Indexed keywords

CRE RECOMBINASE; LENTIVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL LINE; CELL STRAIN HEK293; CONTROLLED STUDY; DNA FLANKING REGION; DNA RESPONSIVE ELEMENT; EMBRYO; FEMALE; GENE CASSETTE; GENE DELETION; GENE INSERTION; GENETIC TRANSFECTION; HUMAN IMMUNODEFICIENCY VIRUS 1; LONG TERMINAL REPEAT; LOXP SITE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; REV GENE; RISK FACTOR; TRANSGENE; VIRAL GENE THERAPY; VIRUS DNA CELL DNA INTERACTION; VIRUS GENE; VIRUS PARTICLE; VIRUS TITRATION;

EID: 84874360062     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.2700     Document Type: Article

References (34)

1. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-265.
2. Zufferey R, Nagy D, Mandel RJ, et al. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15: 871-875.
3. Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72: 9873-9880.
4. Dull T, Zufferey R, Kelly M, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72: 8463-8471.
5. Miyoshi H, Blömer U, Takahashi M, et al. Development of a self-inactivating lentivirus vector. J Virol 1998; 72: 8150-8157.
6. Farson D, Witt R, Mcguinness R, et al. (2001) A new-generation stable inducible packaging cell line for lentiviral vectors. Hum Gene Ther 2001; 12: 981-997.
7. US Patent Number 6218 181. PCT/US99/05982, issued 17 April 2001.
8. Ni Y, Sun S, Oparaocha I, et al. Generation of a packaging cell line for prolonged large-scale production of high-titer HIV-1-based lentiviral vector. J Gene Med 2005; 7: 818-834.
9. Palma MD, Montini E, Santoni de Sio FR, et al. Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary haematopoietic cells. Blood 2005; 105: 2307-2315.
10. Schröder ARW, Shinn P, Chen H, et al. HIV-1 Integration in the human genome favours active genes and local hotspots. Cell 2002; 110: 521-529.
11. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007; 318: 1917-20.
12. Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 2010; 467: 318-322.
13. Ebert AD, Yu J, Rose FF Jr, et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009; 457: 277-280.
14. Chang CW, Lai YS, Pawlik KM, et al. Polycistronic lentiviral vector for 'hit and run' reprogramming of adult skin fibroblasts to induced pluripotent stem cells. Stem Cells 2009; 27: 1042-1049.
15. Bergemann J, Kuhicke K, Fehse B, et al. Excision of specific DNA-sequences from integrated retroviral vectors via site-specific recombination. Nucleic Acids Res 1995; 23: 4451-4456.
16. Pfeifer A, Brandon EP, Kootstra N, et al. Delivery of the Cre recombinase by a self-deleting lentiviral vector: efficient gene targeting in vivo. PNAS 2001; 98: 11450-11455.
17. Morrow CD, Park J, Wakefield JK. Viral gene products and replication of the human immunodeficiency type 1 virus. Am J Physiol 1994; 266: C1135-1156.
18. Arts EJ, Wainberg MA. Human immunodeficiency virus type 1 reverse transcriptase and early events in reverse transcription. Adv Virus Res 1996; 46: 197-163.
19. Watts JM, Dang KK, Gorelick RJ, et al. Architecture and secondary structure of an entire HIV-1 RNA genome. Nature 2009; 460: 711-716.
20. IVS-2-654-thalassemia syndrome in model mice. Hum Gene Ther 2010; 21: 149-156.
21. Aker M, Tubb J, Groth AC, et al. Extended core sequences from the cHS4 insulator are necessary for protecting retroviral vectors from silencing position effects. Hum Gene Ther 2007; 18: 333-343.
22. Hanawa H, Yamamoto M, Zhao HF, et al. Optimized lentiviral vector design improves titer and trangene expression of vector containing the chicken β-globin locus HS4 insulator. Mol Ther 2009; 17: 667-674.
23. Schambach A, Galla M, Maetzig T, et al. Improving transcriptional termination of self-inactivating gamma-retroviral and lentiviral vectors. Mol Ther 2007; 15: 1167-1173.
24. Zhang J, Guo X, Xie S, et al. Production of transgenic mice carrying green fluorescence protein gene by a lentiviral vector-mediated approach. Progr Natural Sci 2006; 16: 47-53.
25. Lois C, Hong EJ, Pease S, et al. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 2002; 295: 868-872.
26. Hogan B, Beddington R, Costantini F, et al. Manipulating the Mouse Embryo, A Laboratory Manual (2nd edn). Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1994.
27. Lewis J, Yang B, Kim R, et al. A common human β-globin splicing mutation modelled in mice. Blood 1998; 91: 2152-2156.
28. Sambrook J, Fitsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Press: Cold Spring Harbor, 1989.
29. Koldej RM, Anson DS. Refinement of lentiviral vector for improved RNA processing and reduced rates of self inactivation repair. BMC Biotechnol 2009; 9: 86-98.
30. Turlo KA, Gallaher SD, Vora R, et al. When Cre-mediated recombination in mice does not result in protein loss. Genetics 2010; 186: 959-967.
31. Silver DP, Livingston DM. Self-excising retroviral vectors encoding the Cre recombinase overcome Cre-mediated cellular toxicity. Mol Cell 2001; 8: 233-243.
32. Zaiss AK, Son S, Chang LJ. RNA 3' readthrough of oncoretrovirus and lentivirus: implications for vector safety and efficacy. J Virol 2002; 76: 7209-7219.
33. Yang Q, Lucas A, Son S, et al. Overlapping enhancer/promoter and transcriptional termination signals in the lentiviral long-terminal repeat. Retrovirology 2007; 4: 1-8.
34. Ramezani A, Hawley TS, Hawley RG. Combinatorial incorporation of enhancer-blocking components of the chicken β-globin 5'HS4 and human T-cell receptor α/δBEAD-1 insulators in self-inactivating retroviral vectors reduces their genotoxic potential. Stem Cells 2008; 26: 3257-3266.